&amp;lt;i&amp;gt;Toxoplasma gondii&amp;lt;/i&amp;gt; But Not &amp;lt;i&amp;gt;Leishmania major&amp;lt;/i&amp;gt; or &amp;lt;i&amp;gt;Trichomonas vaginalis&amp;lt;/i&amp;gt; Decreases Cell Proliferation and Increases Cell Death on Fibrosarcoma Cancer Cells in Culture Medium

Shirzad, Hedayatollah; Khorami, Soleiman; Soozangar, Narges; Yousefi, Mortaza; Darani, Hossein Yousofi

doi:10.4236/wjv.2012.22014

Cited by 13 publications

(9 citation statements)

References 16 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, interestingly parasite stages and parasite antigens are proposed for immunotherapy of asthma (Rzepecka and Harnett 2013) or cancers , respectively. Inhibitory effects of some parasites such as Toxoplasma gondii (Darani et al 2009;Kim et al 2007;Shirzad et al 2012), Hydatid cyst (Aref et al 2012;Yousofi Darani et al 2012), Toxocara canis (Darani et al 2009) and Trypanosoma cruzi (Kallinikova et al 2006;Mel'nikov 2004) on tumor growth has been shown in culture medium or animal model. So immunotherapy with parasitic antigens may be an interesting line of research in the future.…”

Section: Discussionmentioning

confidence: 99%

Parasites and immunotherapy: with or against?

et al. 2014

Self Cite

View full text Add to dashboard Cite

Immunotherapy is a sort of therapy in which antibody or antigen administrates to the patient in order to treat or reduce the severity of complications of disease. This kind of treatment practiced in a wide variety of diseases including infectious diseases, autoimmune disorders, cancers and allergy. Successful and unsuccessful immunotherapeutic strategies have been practiced in variety of parasitic infections. On the other hand parasites or parasite antigens have also been considered for immunotherapy against other diseases such as cancer, asthma and multiple sclerosis. In this paper immunotherapy against common parasitic infections, and also immunotherapy of cancer, asthma and multiple sclerosis with parasites or parasite antigens have been reviewed.

show abstract

Section: Discussionmentioning

confidence: 99%

Parasites and immunotherapy: with or against?

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, other parasites such as Trypanosoma cruzi [6], Toxoplasma gondii [7] and Echinococcus granulosus [8] produce metabolites with anticancer properties.…”

Section: Introductionmentioning

confidence: 99%

Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer

et al. 2018

View full text Add to dashboard Cite

EgKI-1, a member of the Kunitz type protease inhibitor family, is highly expressed by the oncosphere of the canine tapeworm Echinococcus granulosus, the stage that is infectious to humans and ungulates, giving rise to a hydatid cyst localized to the liver and other organs. Larval protoscoleces, which develop within the hydatid cyst, have been shown to possess anti-cancer properties, although the precise molecules involved have not been identified. We show that recombinant EgKI-1 inhibits the growth and migration of a range of human cancers including breast, melanoma and cervical cancer cell lines in a dose-dependent manner in vitro without affecting normal cell growth. Furthermore, EgKI-1 treatment arrested the cancer cell growth by disrupting the cell cycle and induced apoptosis of cancer cells in vitro. An in vivo model of triple negative breast cancer (MDA-MB-231) in BALB/c nude mice showed significant tumor growth reduction in EgKI-1-treated mice compared with controls. These findings indicate that EgKI-1 shows promise for future development as an anti-cancer therapeutic.

show abstract

“…Several parasites, including the liver flukes, Opisthorchis viverrini and Clonorchis sinensis , and the blood fluke, Schistosoma haematobium , are known risk factors for cholangiocarcinoma and bladder cancer, respectively (5). In contrast, other parasites such as Trypanosoma cruzi (6), Toxoplasma gondii (7) and Echinococcus granulosus (8) produce metabolites with anticancer properties.…”

Section: Introductionmentioning

confidence: 99%

Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising anti-cancer therapeutic

Boyle

Fischer

et al. 2018

Preprint

View full text Add to dashboard Cite

34EgKI-1, a member of the Kunitz type protease inhibitor family, is highly expressed by the 35 oncosphere of the canine tapeworm Echinococcus granulosus, the stage that is infectious to 36 humans and ungulates, giving rise to a hydatid cyst localized to the liver and other organs. 37 Larval protoscoleces, which develop within the hydatid cyst, have been shown to possess 38 65 neutrophils. Neutrophil elastase also acts as a chemoattractant for more neutrophils (12). 66 Therefore, potent neutrophil elastase inhibitors have stimulated much interest for 67 development as cancer therapeutics (13). 68The larval stage of the canine tapeworm (phylum Cestoda) E. granulosus causes 69 echinococcosis (hydatidosis) in humans and ungulates (sheep, goats, cattle etc) when they 70 ingest the parasite eggs containing oncospheres in contaminated food or water (14). The 71 oncospheres hatch and penetrate the intestinal mucosa, enter the blood stream and migrate to 72 the liver or lung. A fluid-filled larva begins to develop from a single oncosphere with 73 subsequent formation of multiple layers, resulting in a metacestode or hydatid cyst (15). 74Protoscoleces, which develop asexually within the hydatid cyst, have been shown to induce 75 the death of fibrosarcoma cells although the specific molecules involved have not been 76 identified (8). We have shown that EgKI-1, a member of the Kunitz type protease inhibitor 77 family, is highly expressed in oncospheres, is a potent neutrophil elastase and chemotaxis 78 inhibitor (16) and was recently granted an International Patent Publication (17). 79In this study, recombinant EgKI-1 was expressed in yeast, purified and investigated for 80 potential anti-cancer properties in vitro and in vivo. 82 Methods 83EgKI-1 expression in yeast 84 The pPICZαA plasmid containing the EgKI-1 gene sequence and EcoRI/ XbaI cloning sites 85 was synthesized by Biomatik (Wilmington, USA). The plasmid (10 ng) was then transformed 86 into E. coli XL1-Blue competent cells (Stratagene, San Diego, USA) and sequenced to 87 confirm the integrity of the insertion. Vector bearing the confirmed sequence was inserted 88 into Pichia pastoris KM71H cells using the electroporation method described by 89 Invitrogen TM (Carlsbad, USA). Briefly, a single colony of XL1-Blue cells, bearing the 90 confirmed EgKI-1 sequence isolated from a low salt LB agar plate, was grown in 5 ml of low 91 salt LB medium. From these cells, DNA was extracted using a Plasmid Midi kit (Qiagen, 92 Hilden, Germany). DNA was linearized with SacI-HF (New England BioLabs, Ipswich, 93 USA), extracted using phenol/chloroform and re-suspended in 10 mM Tris (pH 8.5) buffer. 94Linearized DNA (25 µg) was then mixed with 80 µl KM71H cells on ice and transferred to a 95 0.2 cm cuvette and an electric shock applied using Gene Pulser (Biorad, Hercules, USA). 96 Then 1 ml of 1 M sorbitol + 200 µl HEPES mixture was added to the cells and transferred to 4 97 a 10 ml tube. Cells were then incubated for 1.5 hours at 30 o C, plated on YPD agar 98 ...

show abstract

<i>Toxoplasma gondii</i> But Not <i>Leishmania major</i> or <i>Trichomonas vaginalis</i> Decreases Cell Proliferation and Increases Cell Death on Fibrosarcoma Cancer Cells in Culture Medium

Cited by 13 publications

References 16 publications

Parasites and immunotherapy: with or against?

Parasites and immunotherapy: with or against?

Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer

Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising anti-cancer therapeutic

Contact Info

Product

Resources

About